celltelligence

Media platform delivering contextual #cell & #gene #therapy #market #insights and #news for #lifesciences and #biotwitter.

[celltelligence @celltelligence]

On Monday, April 22, the CHMP Agenda (https://t.co/utxsJzhOPw) for April was released. Of note, obe-cel ( $AUTL ’s #CD19 CAR-T) was included in the “Start of Procedure for New Application” section for the treatment of adult patients with r/r B-ALL...: https://t.co/0P3DGoXMy7

[celltelligence @celltelligence]

On Tuesday, April 16, $JNJ held its Q1 2024 earnings call (press release: https://t.co/FmhnZu7lHE / presentation: https://t.co/stYnnoYljk) mentioning #Carvykti’s (#BCMA CAR-T) revenue remained approximately flat. Additionally, management remarked on...: https://t.co/0U1yo4ylck

[celltelligence @celltelligence]

#AACR24 Analysis 3: #Kelonia and $CARM presented preclinical updates from their programs using innovative #celltherapy platforms. Celltelligence provides insights and key context for selected presentations...: https://t.co/pTIhZWQJJT

[celltelligence @celltelligence]

#AACR24 Analysis 2: $PSTX, $CRBU, and $TAK presented clinical and preclinical updates from their programs in hematological malignancies. Celltelligence provides insights and key context for selected presentations: https://t.co/zbvp80zsOz

[celltelligence @celltelligence]

#AACR24 Analysis 1: $CRSP $AZN and $INKT presented clinical and preclinical updates from their programs in solid tumors. Celltelligence provides insights and key context for selected presentations...: https://t.co/e5pqUSb6gS

[celltelligence @celltelligence]

On Friday, April 5, $JNJ (press release: https://t.co/BoJ4VJ8B3J) and $LEGN (press release: https://t.co/0wmz7ln8v8) announced that the FDA approved #Carvykti (#BCMA CAR-T) for the treatment of adult patients with r/r MM who have received at least...: https://t.co/o8SVoYXwCh

[celltelligence @celltelligence]

In the past week, the Celltelligence team detected relevant news that was not discussed in individual blasts but worth highlighting. In this blast, Celltelligence will cover the following topics...: https://t.co/Zh2DK3Lmtv

[celltelligence @celltelligence]

On Friday, March 15, $JNJ (press release: https://t.co/XgUraQx6ie) and $LEGN (press release: https://t.co/eszFIB44wu) announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended #Carvykti (#BCMA CAR-T) for the treatment of adult...: https://t.co/cNE3USyeQ5

[celltelligence @celltelligence]

On Thursday, March 14, $ALLO held its Q4 and FY 2023 earnings call (press release: https://t.co/9kmi7KTRjg), noting that the start-up activities for the pivotal Ph2 #ALPHA3 trial evaluating cema-cel (formerly ALLO-501A; allogeneic #CD19 CAR-T) as...: https://t.co/x2iicyrdVS

[celltelligence @celltelligence]

On Monday, March 18, the CHMP Agenda (https://t.co/5z8SEvd81f) for March was released. Of note, no #celltherapy-related updates were observed.

Therefore, based on the agenda, no updates are expected to be published on the CHMP highlights on March 22: https://t.co/21t2vcm2kk

[celltelligence @celltelligence]

On Thursday, March 14, $BMY announced (press release: https://t.co/uEG8aVVGcp) that the FDA granted accelerated approval (AA) of #Breyanzi (#CD19 CAR-T) for the treatment of chronic lymphocytic #leukemia (#CLL) and small lymphocytic lymphoma (#SLL)...: https://t.co/fLTZxkXGKP

[celltelligence @celltelligence]

On Thursday, March 14, $AUTL held its Q4 2024 earnings call (press release: https://t.co/IuHLcNeQwQ presentation: https://t.co/mh1yu58sxg) highlighting the recent submission of a Market Authorization Application (MAA) for obe-cel (#CD19 CAR-T) in r/r...: https://t.co/adhAayFD4d

[celltelligence @celltelligence]

On Monday, March 11, $CRBU released its Q4 and FY 2023 results (press release: https://t.co/zv49ttbCn9) highlighting that an updated timeline for the initiation of CB-010’s (allogeneic #CD19 CAR-T) pivotal Ph3 trial in ≥2L LBCL is expected in Q2 2024...: https://t.co/lJi7v7NKmf

[celltelligence @celltelligence]

On Thursday, March 7, $PSTX released its Q4 and FY 2023 business updates (press release: https://t.co/V2RBYAgnOQ) highlighting clinical results from its lead asset P-BCMA-ALLO1’s (allogeneic #BCMA CAR-T) Ph1 trial (https://t.co/HO8fWv8Y8L) in r/r MM...: https://t.co/SB6WjSH1n9

[celltelligence @celltelligence]

On Thursday, March 7, a new $BMY-sponsored Ph2 trial (https://t.co/juTbAXfPoh) (#QUINTESSENTIAL) evaluating BMS-986393 (CC-95266; #GPRC5D CAR-T) in quadruple-class exposed [including: an immune modulatory drug (#IMiD), a proteasome inhibitor (PI), an...: https://t.co/FwT87fPSDJ

[celltelligence @celltelligence]

On March 6, $ADAP held its Q4 2023 earnings call (press release: https://t.co/0aNfRJfnBv / webcast: https://t.co/8oC6cmJ3Rf) highlighting the company’s preparation for the potential launch of afami-cel in Q3 2024 in the US. Celltelligence provides...: https://t.co/GsDMLy5Z2i

[celltelligence @celltelligence]

On Tuesday, March 5, $TSVT held its Q4 and FY 2023 earnings call (press release: https://t.co/kwOZgZMegt / webcast: https://t.co/ICqxewlfnk) acknowledging the decline in #Abecma ( $BMY / $TSVT ’s #BCMA CAR-T) sales in the US...: https://t.co/Gpe4o89X1p

[celltelligence @celltelligence]

On Thursday, February 28, $ACLX released its Q4 and FY 2023 results (press release: https://t.co/GLaSt2hMoZ) highlighting the recent expansion of the partnership agreement with $GILD (Kite). Moreover, as disclosed in a SEC filing, the companies are...: https://t.co/GdNLcXrpCZ

[celltelligence @celltelligence]

On Friday, February 23, the CHMP meeting highlights (https://t.co/WXr5DtKToX) were released, including the positive opinion (https://t.co/gqk4BxddyX) of the CHMP for #Carvykti ( $JNJ / $LEGN ’s #BCMA CAR-T) in ≥2L MM.

Celltelligence provides insights...: https://t.co/StaIdnoUOs

[celltelligence @celltelligence]

On Friday, February 16, $IOVA announced (press release: https://t.co/XH26VYNYB3) that the FDA granted accelerated approval to #Amtagvi (#lifileucel), a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy to treat adult patients with...: https://t.co/Q1oplbo1za